SNDX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Syndax Pharmaceuticals Inc (SNDX) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong revenue growth, bullish technical indicators, positive analyst ratings, and favorable options sentiment make it a compelling investment opportunity despite recent net losses.
The stock is showing bullish momentum with SMA_5 > SMA_20 > SMA_200, a positive MACD histogram, and RSI at a neutral level of 55.987. Key support is at 19.696, and resistance is at 22.348, indicating room for upward movement.
Revenue growth of 794.9% YoY in Q4 2025, driven by strong performance from key drugs Revuforj and Niktimvo.
Positive analyst ratings with raised price targets (Citi: $57, BofA: $28).
Bullish technical indicators and favorable options sentiment.
Net loss of $68.01 million in Q4 2025, with a YoY decline in net income and EPS.
No significant insider or hedge fund trading trends.
In Q4 2025, revenue surged by 794.9% YoY to $68.73 million, while net income dropped by 27.77% YoY to -$68.01 million. EPS decreased by 28.44% YoY to -0.78, but gross margin improved by 7.64% YoY to 96.06%.
Analysts are bullish on SNDX. Citi raised its price target to $57 from $51, and BofA increased its target to $28 from $27, both maintaining Buy ratings.
